RT Journal Article
SR Electronic
T1 Patterns of convergence and divergence between bipolar disorder type I and type II: evidence from integrative genomic analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267813
DO 10.1101/2021.12.15.21267813
A1 Huang, Yunqi
A1 Liu, Yunjia
A1 Wu, Yulu
A1 Tang, Yiguo
A1 Liu, Siyi
A1 Xiao, Liling
A1 Zhang, Mengting
A1 Tao, Shiwan
A1 Xie, Min
A1 Dai, Minhan
A1 Li, Mingli
A1 Gui, Hongsheng
A1 Wang, Qiang
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267813.abstract
AB Genome-wide association studies (GWAS) analyses have revealed genetic evidence of bipolar disorder (BD), but little is known about genetic structure of BD subtypes. We aimed to investigate genetic overlap and distinction of bipolar type I (BDI) & type II (BDII) by conducting integrative post-GWAS analyses. This study utilized single nucleotide polymorphism (SNP)-level approaches to uncover correlated and distinct genetic loci. Transcriptome-wide association analyses (TWAS) were then approached to pinpoint functional genes expressed in specific brain tissues and blood. Next, we performed cross-phenotype analysis including exploring the potential causal associations between BDI & II and drug responses and comparing the difference of genetic structures among four different psychiatric traits. Our results find SNP-level evidence revealed three genomic loci, SLC25A17, ZNF184 and RPL10AP3 shared by BDI & II, while one locus (i.e., MAD1L1) and significant gene sets involved in calcium channel activity, neural and synapsed signals that distinguished two subtypes. TWAS data implicated different genes effecting BDI & II through expression in specific brain regions (e.g., nucleus accumbens for BDI). Cross-phenotype analyses indicated that BDI & II share continuous genetic structures with schizophrenia (SCZ) and major depression disorder (MDD), which help fill the gaps left by the dichotomy of mental disorder. These combined evidences illustrate genetic convergence and divergence between BDI & II and provide an underlying biological and trans-diagnostic insight into major psychiatric disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Nature Science Foundation of China (Grant NO.81771446 to QW, NO.82171499 to QW and 82071524 to ML), Science and Technology Project of Sichuan Province (2021YJ0238 to ML). HG is supported by Mentored Scientist Grant in Henry Ford Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only available human data, which can be obtained from the Psychiatric Genomics Consortium Bipolar Disorder Working Group (PGC3 BD), containing BDI (25,060 cases and 449,978 controls from 55 cohorts, effective N = 64,802) and BDII (6,781 cases, 364,075 controls from 31 cohorts, effective N = 22,560), respectively. Details on participant and cohort information, quality control can be accessed online (https://www.med.unc.edu/pgc/). Nominal significant instrumental variants (IVs) of lithium salt17-19 were downloaded from National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS Catalog20 (https://www.ebi.ac.uk/). The latest and biggest GWA meta-analysis summary statistics for SCZ (69,369 cases; 236,642controls)21, and MDD except samples in 23andMe dataset (59,851 cases and 113,154 controls)22 were also downloaded from PGC website.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript. All data produced are available online at the Psychiatric Genomics Consortium Bipolar Disorder Working Group (PGC3 BD) and National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS Catalog20 (https://www.ebi.ac.uk/) and PGC website. https://www.med.unc.edu/pgc/ https://www.ebi.ac.uk/